In a meta-analysis of GLP-1 RA and SGLT2i clinical trials, the authors concluded that the prevention of heart failure and kidney disease progression by SGLT2is should be considered in the decision-making process when treating people with T2D [99]; although SGLT2is may be preferred over GLP-1 RAs in select patients. This evidence concerns the gene GLP1R and kidney disorder.